Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 21-28 |
| Number of pages | 8 |
| Journal | Cancer Treatment Reviews |
| Volume | 69 |
| DOIs | |
| Publication status | Published - 2018 |
Keywords
- Immune check-point inhibitors
- Immune related adverse events
- Melanoma
- PDL-1
- Vitamin D
- beta3 integrin
- calcitriol
- calcium
- cathelicidin
- checkpoint kinase inhibitor
- colecalciferol
- cyclin dependent kinase inhibitor 1
- cyclin dependent kinase inhibitor 1B
- ergocalciferol
- glucocorticoid
- infliximab
- interleukin 12
- interleukin 17
- ipilimumab
- mitogen activated protein kinase
- nivolumab
- osteoclast differentiation factor
- osteopontin
- oxygenase
- phosphatidylinositol 3 kinase
- placebo
- protein kinase B
- S100 calcium binding protein G
- somatomedin binding protein
- vitamin D
- vitamin D receptor
- CD274 protein, human
- cytotoxic T lymphocyte antigen 4
- monoclonal antibody
- programmed death 1 ligand 1
- adaptive immunity
- antineoplastic activity
- antiproliferative activity
- apoptosis
- calcium absorption
- cancer survival
- cell cycle progression
- cell differentiation
- cell proliferation
- colitis
- conformational transition
- diarrhea
- down regulation
- drug absorption
- drug receptor binding
- drug structure
- epithelium cell
- helper cell
- human
- hypertransaminasemia
- immunocompetent cell
- immunomodulation
- immunoregulation
- innate immunity
- loading drug dose
- melanoma
- overall survival
- progression free survival
- protein cleavage
- protein expression
- protein function
- Review
- Th17 cell
- tumor microenvironment
- ultraviolet radiation
- upregulation
- vitamin D deficiency
- vitamin supplementation
- antagonists and inhibitors
- combination drug therapy
- prognosis
- Antibodies, Monoclonal
- B7-H1 Antigen
- CTLA-4 Antigen
- Drug Therapy, Combination
- Humans
- Prognosis
Fingerprint
Dive into the research topics of 'Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors. / Stucci, L.S.; D'Oronzo, S.; Tucci, M. et al.
In: Cancer Treatment Reviews, Vol. 69, 2018, p. 21-28.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors
AU - Stucci, L.S.
AU - D'Oronzo, S.
AU - Tucci, M.
AU - Macerollo, A.
AU - Ribero, S.
AU - Spagnolo, F.
AU - Marra, E.
AU - Picasso, V.
AU - Orgiano, L.
AU - Marconcini, R.
AU - De Rosa, F.
AU - Guardo, L.D.
AU - Galli, G.
AU - Gandini, S.
AU - Palmirotta, R.
AU - Palmieri, G.
AU - Queirolo, P.
AU - Silvestris, F.
AU - (IMI), for the Italian Melanoma Intergroup
N1 - Export Date: 5 February 2019 CODEN: CTRED Correspondence Address: D'Oronzo, S.; Medical Oncology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, P.za Giulio Cesare, 11, Italy; email: stella.doronzo@uniba.it Chemicals/CAS: beta3 integrin, 166873-01-4; calcitriol, 32222-06-3, 32511-63-0, 66772-14-3; calcium, 7440-70-2, 14092-94-5; cathelicidin, 170006-50-5; colecalciferol, 1406-16-2, 67-97-0; ergocalciferol, 50-14-6, 50809-47-7, 8042-78-2; infliximab, 170277-31-3; interleukin 12, 138415-13-1; ipilimumab, 477202-00-9; mitogen activated protein kinase, 142243-02-5; nivolumab, 946414-94-4; osteoclast differentiation factor, 200145-93-3; osteopontin, 106441-73-0; oxygenase, 9037-29-0, 9046-59-7; phosphatidylinositol 3 kinase, 115926-52-8; protein kinase B, 148640-14-6; Antibodies, Monoclonal; B7-H1 Antigen; CD274 protein, human; CTLA-4 Antigen; Vitamin D Funding details: Associazione Italiana per la Ricerca sul Cancro, AIRC, 17536 Funding details: Associazione Italiana per la Ricerca sul Cancro, AIRC Funding text 1: This work was funded by a grant from AIRC (Italian Association for Cancer Research) number 17536. References: Lo, M.C.I., Maraka, J., Garioch, J., John, W.G., Moncrieff, M., Monitoring vitamin D in the patient with melanoma: impact of sun avoidance on vitamin D levels of patients with melanoma at a U.K. tertiary-referral melanoma service (2017) Br J Dermatol, 177, pp. 282-283; Fang, S., Sui, D., Wang, Y., Liu, H., Chiang, Y.C., Ross, I.M., Association of vitamin D levels with outcome in patients with melanoma after adjustment for C-reactive protein (2016) J Clin Oncol, 34 (15), pp. 1741-1747; Saw, R.P., Armstrong, B.K., Mason, R.S., Morton, R.L., Shannon, K.S., Spillane, A.J., (2014), 14, p. 780. , Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: a placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D). BMC Cancer; Spath, L., Ulivieri, A., Lavra, L., Fidanza, L., Carlesimo, M., Giubettini, M., (2017), 7, p. 40370. , Antiproliferative effects of 1α-OH-vitD3 in malignant melanoma: potential therapeutic implications. Sci Rep; Daniel, C., Sartory, N.A., Zahn, N., Radeke, H.H., Stein, J.M., Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile (2008) J Pharmacol Exp Ther, 324 (1), pp. 23-33; Sotirchos, E.S., Bhargava, P., Eckstein, C., Van Haren, K., Baynes, M., Ntranos, A., Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis (2016) Neurology, 86, pp. 382-390; Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Combined nivolumab and ipilimumab or monotherapy in untreated melanoma (2015) N Engl J Med, 373, pp. 1270-1271; Ombra, M.N., Paliogiannis, P., Doneddu, V., Sini, M.C., Colombino, M., Rozzo, R., Vitamin D status and risk for malignant cutaneous melanoma: recent advances (2017) Eur J Cancer Prev, 26, pp. 263-267; Norman, A.W., From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health (2008) Am J Clin Nutr, 88, pp. 491S-499S; Christakos, S., Dhawan, P., Verstuyf, A., Verlinden, L., Carmeliet, G., Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects (2016) Physiol Rev, 96, pp. 365-408; D'Oronzo, S., Stucci, S., Tucci, M., Silvestris, F., Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications (2015) Cancer Treat Rev, 41 (9), pp. 798-808; Wacker, M., Holick, M.F., Vitamin D-effects on skeletal and extraskeletal health and the need for supplementation (2013) Nutrients, 5, pp. 111-148; Campbell, M.J., Trump, D.L., Vitamin D receptor signaling and cancer (2017) Endocrinol Metab Clin North Am, 46, pp. 1009-1038; Cafforio, P., D'Oronzo, S., Felici, C., Sigala, S., Fragni, M., Silvestris, F., 1,25(OH)2 vitamin D(3) contributes to osteoclast-like trans-differentiation of malignant plasma cells (2017) Exp Cell Res, 358 (2), pp. 260-268; Wang, T.T., Nestel, F.P., Bourdeau, V., Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression (2004) J immunol, 173 (5), pp. 2909-2912; Jacobs, E.T., Kohler, L.N., Kunihiro, A.G., Jurutka, P.W., Vitamin D and colorectal, breast, and prostate cancers: a review of the epidemiological evidence (2016) J Cancer, 7, pp. 232-240; Colston, K., Coloston, M.J., Feldman, D., 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture (1981) Endocrinology, 108 (3), pp. 1083-1086; Abe, E., Miyaura, C., Sakagami, H., Takeda, M., Konno, K., Yamazaki, T., Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3 (1981) PNAS, 78 (8), pp. 4990-4994; Flores, O., Wang, Z., Knudsen, K.E., Burnstein, K.L., Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localizzation and cyclin E-mediated growth inhibition (2010) Endocrinology, 151 (3), pp. 896-908; Gocek, E., Studzinski, G.P., Vitamin D and differentiation in cancer (2009) Crit Rev Clin Lab Sci, 46 (4), pp. 190-209; Cohen-Lahav, M., Shany, S., Tobvin, D., Chaimovitz, C., Douvdevani, A., Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels (2006) Nephrol Dial Transplant, 21 (4), pp. 889-897; Fukuda, R., Kelly, B., Semenza, G.L., Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1 (2003) Cancer Res, 63 (9), pp. 2330-2334; Moukayed, M., Grant, W.B., Molecular link between vitamin d and cancer prevention (2013) Nutrients, 5, pp. 3993-4021; Lappe, J.M., Travers-Gustafson, D., Davies, K.M., Recker, R.R., Heaney, R.P., Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial (2008) Am J Clin Nutr, 87 (3), p. 794; Chlebowski, R.T., Johnson, K.C., Kooperberg, C., Pettinger, M., Wactawski-Wende, J., Rohan, T., Calcium plus vitamin D supplementation and the risk of breast cancer (2008) J Natl Cancer Inst, 100 (22), pp. 1581-1591; Grant, W.B., Ecological studies of the UVB-vitamin D-cancer hypothesis (2012) Anticancer Res, 32 (1), pp. 223-236; Zhang, L., Wang, S., Che, X., Li, X., Vitamin D and lung cancer risk: a comprehensive review and meta-analysis (2015) Cell Physiol Biochem, 36, pp. 299-305; Baron, J.A., Barry, E.L., Mott, L.A., Rees, J.R., Sandler, R.S., Snover, D.C., A trial of calcium and vitamin D for the prevention of colorectal adenomas (2015) N Engl J Med, 373 (16), pp. 1519-1530; Yin, L., Ordóñez-Mena, J.M., Chen, T., Schöttker, B., Arndt, V., Brenner, H., Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: a systemic review and meta-analysis (2013) Prev Med, 57 (6), pp. 753-764; Dimitrakopoulou, V.I., Tsilidis, K.K., Haycock, P.C., Dimou, N.L., Al-Dabhani, K., Martin, R.M., Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study (2017) BMJ, 359, p. j4761; Kühn, T., Kaaks, R., Becker, S., Eomois, P.P., Clavel-Chapelon, F., Kvaskoff, M., Plasma 25-hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: a nested case-control study (2013) Int J Cancer, 133 (7), pp. 1689-1700; Scarmo, S., Afanasyeva, Y., Lenner, P., Koenig, K.L., Horst, R.L., Clendenen, T.V., Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: a nested case-control study (2013) Breast Cancer Res, 15 (1), p. R15; Gallicchio, L., Helzlsouer, K.J., Chow, W.H., Freedman, D.M., Hankinson, S.E., Hartge, P., Circulating 25-hydroxyvitamin D and risk of Kidney cancer: cohort consortium vitamin D pooling project of rarer cancers (2010) Am J Epidemiol, 172 (1), pp. 47-57; Helzlsouer, K.J., Steering, V.D.P.P., Committee, Overview of the cohort consortium vitamin D pooling project of rarer cancers (2010) Am J Epidemiol, 172 (1), pp. 4-9; Bassuk, S.S., Manson, J.E., Lee, I.M., Cook, N.R., Christen, W.G., Bubes, V.Y., Baseline characteristics of partecipants in the VITamin D and OmegA-3 TriaL (VITAL) (2016) Contemp Clin Trials, 47, pp. 235-243; Tagliabue, E., Raimondi, S., Gandini, S., Vitamin, D., Cancer risk, and mortality (2015) Adv Food Nutr Res, 75, pp. 1-52; Field, S., Davies, J., Bishop, T., Newton-Bishop, J.A., Vitamin D and melanoma (2013) Dermato-Endocrinol, 5 (1), pp. 121-129; Ribero, S., Glass, D., Bataille, V., Genetic epidemiology of melanoma (2016) Eur J Dermatol, 26 (4), pp. 335-339; Berwick, M., Erdei, E.O., Vitamin D and melanoma incidence and mortality (2013) Pigment Cell Melanoma Res, 26 (1), pp. 9-15; Ribero, S., Glass, D., Aviv, A., Spector, T.D., Bataille, V., Height and bone mineral density are associated with naevus count supporting the importance of growth in melanoma susceptibility (2015) PLos One, 10 (1), p. e0116863; Böhm, M., Luger, T.A., Tobin, D.J., García-Borrón, J.C., Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology (2006) J Invest Dermatol., 126 (9), pp. 1966-1975; Glass, D., Lens, M., Swaminathan, R., Spector, T.D., Bataille, V., Pigmentation and vitamin D metabolism in Caucasians: low vitamin D serum levels in fair skin types in the UK (2009) PLos One, 4 (8), p. e6477; Ramos-Lopez, E., Brück, P., Jansen, T., Herwig, J., Badenhoop, K., CYP2R1 (vitamin D 25-hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans (2007) Diabetes Metab Res Rev, 23 (8), pp. 631-636; Slominski, A.T., Brożyna, A.A., Zmijewski, M.A., Jóźwicki, W., Jetten, A., Mason, R.S., Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management (2017) Lab Invest, 97 (6), pp. 706-724; Ribero, S., Longo, C., Glass, D., Nathan, P., Bataille, V., What is new in melanoma genetics and treatment? (2016) Dermatology, 232 (3), pp. 259-264; Falchi, M., Bataille, V., Hayward, N.K., Duffy, D.L., Bishop, J.A., Pastinen, T., Genoma-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi (2009) Nat Genet, 41 (8), pp. 915-919; Ribero, S., Glass, D., Mangino, M., Aviv, Spectorm T, Bataille V. Positive association between vitamin D serum levels and naevus counts. Acta Derm Venereol; 2016. is:10.2340/00015555-2583; Bataille, V., Snieder, H., MacGregor, A.J., Sasieni, P., Spector, T.D., Genetics of risk factors for melanoma: an adult twin study of nevi and freckles (2000) J Natl Cancer Inst, 92 (6), pp. 457-463; Williams, D.M., Palaniswamy, S., Sebert, S., Buxton, J.L., Blakemore, A.I., Hyppönen, E., 25-Hydroxyvitamin D concentration and leukocyte telomere length in young adults: findings from the Northern Finland Birth Cohort 1966 (2016) Am J Epidemiol, 183 (3), pp. 191-198; Bataillle, V., Kato, B.S., Falchi, M., Gardner, J., Kimura, M., Lens, M., Nevus size and nember are associated with telomere length and represent potential markers of a decreased senescence in vivo (2007) Cancer Epidemiol Biomarkers Prev, 16 (7), pp. 1499-1502; Sinikumpu, S.P., Huilaja, L., Jokelainen, J., Auvinen, J., Timonen, M., Kaisa Tasanen, K., Association of multiple Melanocytic Naevi with education, sex and skin type: a Northern Finland Birth Cohort 1966 study with 46 years’ follow-up (2017) Acta Derm Venereol, 97 (2), pp. 219-224; Stenehjem, J.S., Grimsrud, T.K., Rees, J.R., Vos, L., Babigumira, R., Veierød, M.B., A protocol for prospective studies of 25-hydroxyvitamin D, leptin and body mass index in relationto cutaneous melanoma incidence and survival. BMJ Open 2017;21, 7(6):e014829; Sondak, V.K., McIver, B., Kanetsky, P.A., Vitamin D and melanoma: what do we tell our patients? (2016) J Clin Oncol, 34 (15), pp. 1713-1714; Chung, I., Han, G., Seshadri, M., Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo (2009) Cancer Res, 69 (3), pp. 967-975; Newton-Bishop, J.A., Beswick, S., Randerson-Moon, J., Chang, Y.M., Affleck, P., Elliott, F., Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma (2009) J Clin Oncol, 27, pp. 5439-5444; Timerman, D., McEnery-Stonelake, M., Joyce, C.J., Nambudiri, V.E., Hodi, F.S., Claus, E.B., Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma. Oncotarget 2016;8(4); Nürnberg, B., Gräber, S., Gärtner, B., Geisel, J., Pföhler, C., Schadendorf, D., Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients (2009) Anticancer Res, 29 (9), pp. 3669-3674; De Smedt, J., Van Kelst, S., Boecxstaens, V., Stas, M., Bogaerts, K., Vanderschueren, D., Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial (2017) BMC Cancer, 17 (1), p. 562; Gandini, S., Montella, M., Ayala, F., Benedetto, L., Rossi, C.R., Vecchiato, A., Clinical national melanoma registry group (2016) Oncol Lett, 11 (4), pp. 2706-2714; Balvers, M.G.J., Brouwer-Brolsma, E.M., Endenburg, S., de Groot, L.C.P.G.M., Kok, F.J., Gunnewiek, J.K., (2015), 4, p. e23. , Recommended intakes of vitamin D to optimise health, associated circulating 25-hydroxyvitamin D concentrations, and dosing regimens to treat deficiency: workshop report and overview of current literature. J Nutr Sci; Korgavkar, K., Xiong, M., Weinstock, M.A., Review: Higher vitamin D status and supplementation may be associated with risks (2014) Eur J Dermatol, 24, pp. 428-434; Chang, Y., Barrett, J.H., Bishop, D.T., Armstrong, B.K., Bataille, V., Bergman, W., Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls (2009) Int J Epidemiol, 38 (3), pp. 814-830; Tang, J.Y., Fu, T., LeBlanc, E., Manson, J.E., Feldman, D., Linos, E., Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial (2011) J Clin Oncol, 29 (22), pp. 3078-3084; Gandini, S., Raimondi, S., Gnagnarella, P., Doré, J.F., Maisonneuve, P., Testori, A., Vitamin D and skin cancer: a meta-analysis (2009) Eur J Cancer, 45 (4), pp. 634-641; Egan, K.M., Sosman, J.A., Blot, W.J., Sunlight and reduced risk of cancer: is the real story vitamin D? (2005) JNCI J Natl Cancer Inst, 97 (3), pp. 161-163; Hewison, M., Vitamin D and the immune system: new perspectives on an old theme (2010) Endocrinol Metab Clin North Am, 39 (2), pp. 365-379; Liu, P.T., Stenger, S., Li, H., Wenzel, L., Tan, B.H., Krutzik, S.R., Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response (2006) Science, 311 (5768), pp. 1770-1773; Pinheiro da Silva, F., Machado, M.C., Antimicrobial peptides: clinical relevance and therapeutic implications (2012) Peptides, 36 (2), pp. 308-314; Davies, P.D., Brown, R.C., Woodhead, J.S., Serum concentrations of vitamin D metabolites in untreated tuberculosis (1985) Thorax, 40 (3), pp. 187-190; White, J., Vitamin D as an inducer of cathelicidin antimicrobial peptide expression: past, present and future (2010) J Steroid Biochem Molecul Biol, 121, pp. 234-238; Gombart, A.F., Borregaard, N., Koeffler, H.P., Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3 (2005) FASEB J, 19 (9), pp. 1067-1077; Van Etten, E., Mathieu, C., Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts (2005) J Steroid Biochem Mol Biol, 97 (1-2), pp. 93-101; Palmer, M.T., Lee, Y.K., Maynard, C.L., Lineage-specific effects of 1,25- dihydroxyvitamin D(3)on the development of effector CD4 T cells (2011) J Biol Chem, 286 (2), pp. 997-1004; Gregori, S., Casorati, M., Amuchastegui, S., Smiroldo, S., Davalli, A.M., Adorini, L., Regulatory T cells induced by 1α,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance (2001) J Immunol, 167 (4), pp. 1945-1953; Tucci, M., Stucci, S., Savonarola, A., Ciavarella, S., Cafforio, P., Dammacco, F., Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation (2013) Br J Haematol, 161 (6), pp. 821-831; Adorini, L., Penna, G., Control of autoimmune diseases by the vitamin D endocrine system (2008) Nat Clin Pract Rheumatol, 4 (8), pp. 404-412; Littorin, B., Blom, P., Schölin, A., Arnqvist, H.J., Blohmé, G., Bolinder, J., Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS) (2006) Diabetologia, 49 (12), pp. 2847-2852; Luthold, R.V., Fernandes, G.R., Franco-de-Moraes, A.C., Folchetti, L.G., Ferreira, S.R., Gut microbiota interactions with the immunomodulatory role of vitamin D in normal individuals (2017) Metabolism, 69, pp. 76-86; Goswami, R., Marwaha, R.K., Gupta, N., Tandon, N., Sreenivas, V., Tomar, N., Prevalence of vitamin D deficiency and its relationship with thyroid autoimmunity in Asian Indians: a community-based survey (2009) Br J Nutr, 102 (2), pp. 382-386; Wittke, A., Weaver, V., Mahon, B.D., August, A., Cantorna, M.T., Vitamin D receptor-deficient mice fail to develop experimental allergic asthma (2004) J Immunol, 173 (5), pp. 3432-3436; Chiu, C.Y., Huang, S.Y., Peng, Y.C., Tsai, M.H., Hua, M.C., Yao, T.C., Maternal vitamin D levels are inversely related to allergic sensitization and atopic diseases in early childhood (2015) Pediatr Allergy Immunol, 26 (4), pp. 337-343; Amuchastegui, S., Daniel, K.C., Adorini, L., Inhibition of acute and chronic allograft rejection in mouse models by BXL-628, a nonhypercalcemic vitamin D receptor antagonist (2005) Transplantation, 80 (1), pp. 81-87; Sigmundsdottir, H., Pan, J., Debes, G.F., Alt, C., Habtezion, A., Soler, D., DCs metabolize sunlight-induced vitamin D3to ‘program’ T cell attraction to the epidermal chemokine CCL27 (2007) Nat Immunol, 8 (3), pp. 285-293; Chen, S., Sims, G.P., Chen, X.X., Gu, Y.Y., Chen, S., Lipsky, P.E., Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation (2007) J Immunol, 179 (3), pp. 1634-1647; Hewison, M., Zehnder, D., Chakraverty, R., Adams, J.S., Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase (2004) Mol Cell Endocrinol, 215 (1-2), pp. 31-38; Tucci, M., Stucci, S., Strippoli, S., Dammacco, F., Silvestris, F., Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression? (2011) Oncologist, 16, pp. 1040-1048; Hewison, M., Freeman, L., Hughes, S.V., Evans, K.N., Bland, R., Eliopoulos, A.G., Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells (2003) J Immunol, 170 (11), pp. 5382-5390; Dimitrov, V., Bouttier, M., Boukhaled, G., Tabar, S.T., Avramescu, R.A., Memari, B., Hormonal vitamin D upregulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in human but not mouse. J Biol Chem 2017;292(50):jbc.M117.793885; Bendix, M., Greisen, S., Dige, A., Hvas, C.L., Bak, N., Jørgensen, S.P., Vitamin D increases programmed death receptor-1 expression in Crohn's disease (2017) Oncotarget, 8 (15), pp. 24177-24186; Joshi, S., Pantalena, L.C., Liu, X.K., Gaffen, S.L., Liu, H., Rohowsky-Kochan, C., 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A (2011) Mol Cell Biol, 31, pp. 3653-3669; Tarhini, A.A., Zahoor, H., Lin, Y., Malhotra, U., Sander, C., Butterfield, L.H., (2015), 3, p. 39. , Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer; Stucci, S., Palmirotta, R., Passarelli, A., Silvestris, E., Argentiero, A., Lanotte, L., Immune-related adverse events during anticancer immunotherapy: pathogenesis and management (2017) Oncol Lett, 14 (5), pp. 5671-5680
PY - 2018
Y1 - 2018
N2 - The role of vitamin D in melanoma is still controversial. Although several Authors described a correlation between vitamin D deficiency and poor survival in metastatic melanoma patients, clinical trials exploring the effects of vitamin D supplementation in this clinical setting were mostly inconclusive. However, recent evidence suggests that vitamin D exerts both anti-proliferative effects on tumor cells and immune-modulating activities, that have been widely explored in auto-immune disorders. On the one hand, vitamin D has been shown to inhibit T-helper17 lymphocytes, notoriously involved in the pathogenesis of immune-related adverse events (iAEs) which complicate immune-checkpoint inhibitor (ICI) treatment. On the other hand, vitamin D up-regulates PDL-1 expression on both epithelial and immune cells, suggesting a synergic effect in combination with ICIs, for which further investigation is needed. © 2018 Elsevier Ltd
AB - The role of vitamin D in melanoma is still controversial. Although several Authors described a correlation between vitamin D deficiency and poor survival in metastatic melanoma patients, clinical trials exploring the effects of vitamin D supplementation in this clinical setting were mostly inconclusive. However, recent evidence suggests that vitamin D exerts both anti-proliferative effects on tumor cells and immune-modulating activities, that have been widely explored in auto-immune disorders. On the one hand, vitamin D has been shown to inhibit T-helper17 lymphocytes, notoriously involved in the pathogenesis of immune-related adverse events (iAEs) which complicate immune-checkpoint inhibitor (ICI) treatment. On the other hand, vitamin D up-regulates PDL-1 expression on both epithelial and immune cells, suggesting a synergic effect in combination with ICIs, for which further investigation is needed. © 2018 Elsevier Ltd
KW - Immune check-point inhibitors
KW - Immune related adverse events
KW - Melanoma
KW - PDL-1
KW - Vitamin D
KW - beta3 integrin
KW - calcitriol
KW - calcium
KW - cathelicidin
KW - checkpoint kinase inhibitor
KW - colecalciferol
KW - cyclin dependent kinase inhibitor 1
KW - cyclin dependent kinase inhibitor 1B
KW - ergocalciferol
KW - glucocorticoid
KW - infliximab
KW - interleukin 12
KW - interleukin 17
KW - ipilimumab
KW - mitogen activated protein kinase
KW - nivolumab
KW - osteoclast differentiation factor
KW - osteopontin
KW - oxygenase
KW - phosphatidylinositol 3 kinase
KW - placebo
KW - protein kinase B
KW - S100 calcium binding protein G
KW - somatomedin binding protein
KW - vitamin D
KW - vitamin D receptor
KW - CD274 protein, human
KW - cytotoxic T lymphocyte antigen 4
KW - monoclonal antibody
KW - programmed death 1 ligand 1
KW - adaptive immunity
KW - antineoplastic activity
KW - antiproliferative activity
KW - apoptosis
KW - calcium absorption
KW - cancer survival
KW - cell cycle progression
KW - cell differentiation
KW - cell proliferation
KW - colitis
KW - conformational transition
KW - diarrhea
KW - down regulation
KW - drug absorption
KW - drug receptor binding
KW - drug structure
KW - epithelium cell
KW - helper cell
KW - human
KW - hypertransaminasemia
KW - immunocompetent cell
KW - immunomodulation
KW - immunoregulation
KW - innate immunity
KW - loading drug dose
KW - melanoma
KW - overall survival
KW - progression free survival
KW - protein cleavage
KW - protein expression
KW - protein function
KW - Review
KW - Th17 cell
KW - tumor microenvironment
KW - ultraviolet radiation
KW - upregulation
KW - vitamin D deficiency
KW - vitamin supplementation
KW - antagonists and inhibitors
KW - combination drug therapy
KW - prognosis
KW - Antibodies, Monoclonal
KW - B7-H1 Antigen
KW - CTLA-4 Antigen
KW - Drug Therapy, Combination
KW - Humans
KW - Prognosis
U2 - 10.1016/j.ctrv.2018.05.016
DO - 10.1016/j.ctrv.2018.05.016
M3 - Article
VL - 69
SP - 21
EP - 28
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
SN - 0305-7372
ER -